Strides Pharma Science has reported its audited consolidated and standalone financial results for the financial year ended March 31, 2026, delivering strong growth across profitability and efficiency metrics. FY26 consolidated EBITDA stood at ₹9,253M, reflecting a 15.3% year-on-year increase, while EBITDA margin expanded 140 basis points to 19.00%. Operational PAT surged 50.3% YoY to ₹5,181M, with Operational EPS at ₹56.20. On a standalone basis, revenue from operations stood at ₹21,801.35M and profit after tax from continuing operations reached ₹1,836.35M for FY26. The Board recommended a final dividend of ₹5 per equity share for FY26.

FY26 and Q4 Consolidated Financial Highlights

The company's latest performance reflects broad-based growth across quarterly and full-year metrics. The following table presents the consolidated financial highlights:

Reported PAT = PAT from continuing operations; Operational PAT = Reported PAT excluding exceptional items and one-time income

Standalone Financial Performance

On a standalone basis, Strides Pharma reported revenue from operations of ₹21,801.35M for FY26, compared to ₹21,394.23M in FY25. Profit after tax from continuing operations stood at ₹1,836.35M for FY26, against ₹591.56M in the previous year. The standalone results for Q4 FY26 reflect revenue from operations of ₹6,057.35M and profit after tax from continuing operations of ₹163.53M. The following table summarises key standalone financial metrics:

The standalone balance sheet as at March 31, 2026 reflects total assets of ₹53,957.19M (vs. ₹50,309.45M as at March 31, 2025) and total equity of ₹32,835.18M (vs. ₹31,927.35M). Net cash flow generated from operating activities for FY26 stood at ₹2,778.45M, compared to ₹4,214.83M in FY25. The statutory auditor, B S R & Co. LLP, has issued an unmodified opinion on both the standalone and consolidated financial results for FY26.

Geographic Revenue Performance

The updated figures reveal a differentiated growth trajectory across Strides Pharma's key markets. While the US market remains the larger revenue contributor, ex-US markets demonstrated significantly stronger momentum on a year-over-year basis. The table below presents the geographic revenue breakdown:

The company also reported Net Debt at ₹14,365M, impacted by foreign exchange (₹) depreciation of ₹1,115M. Net Debt to EBITDA improved to 1.55x in FY26 from 1.9x in FY25, while RoCE increased to 15.80% from 14.90% over the same period.

Management Commentary

Badree Komandur, MD & Group CEO, commented on the performance: "Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex-US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth."

Dividend Announcement

The Board of Directors recommended a final dividend of ₹5 per equity share of ₹10 each, at the rate of 50%, for the financial year ended March 31, 2026, subject to shareholder approval at the ensuing Annual General Meeting. The proposed dividend is expected to result in a cash outflow of approximately ₹461M. The record date for determining eligible shareholders will be fixed and intimated in due course, with dividend payment to be made within 30 days of shareholder approval.

The Board of Directors of Strides Pharma Science Limited, at their meeting held on May 18, 2026, considered and recommended the appointment of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants, as the company's Statutory Auditors for a term of five consecutive years. The recommendation was made based on the Audit Committee's advice and was disclosed to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The board meeting commenced at 12:30 hrs IST and concluded at 14:15 hrs IST.

Reason for Auditor Rotation

The proposed change in statutory auditors is driven by the mandatory rotation requirement under applicable regulations. M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/W-100022), the existing Statutory Auditors of the company, will complete their second term of five consecutive years upon conclusion of the 36th AGM to be held in the year 2027. As a result, the board has recommended the appointment of a new audit firm in compliance with statutory rotation norms.

Key Details of the Proposed Appointment

The following table summarises the key parameters of the proposed auditor appointment:

Profile of the Incoming Auditor

Deloitte Haskins & Sells LLP has a well-established presence in India. Key details of the firm are as follows:

• Constituted: Deloitte Haskins & Sells, Mumbai was constituted in 1997.
• Converted to LLP: The firm was converted to a Limited Liability Partnership with effect from November 20, 2013.
• ICAI Registration: Registered with the Institute of Chartered Accountants of India (Registration No. 117366W/W-100018).
• Network Affiliation: Part of Deloitte Haskins & Sells & Affiliates, being the Network of Firms registered with the ICAI.
• Registered Office: One International Center, Tower 3, 31st Floor, Senapati Bapat Marg, Elphinstone Road (West), Mumbai - 400013, Maharashtra, India.

Shareholder Approval Process

The proposed appointment of M/s. Deloitte Haskins & Sells LLP is subject to the approval of the shareholders of Strides Pharma Science Limited. Shareholder approval for this matter is to be sought during the 36th AGM, scheduled to be held in the year 2027. The disclosure was made in accordance with Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The information has also been made available on the company's website at www.strides.com .